Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance

Dementia and Geriatric Cognitive Disorders

Volumn 9, Issue 3, 1998, Pages 126-129

  Nybo, Mads ^a   Olsen, Hanne ^a   Jeune, Bernard ^a   Andersen Ranberg, Karen ^a   Nielsen, Ellen Holm ^a   Svehag, Sven Erik ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Alzheimer's disease; Centenarians; Dementia; Plasma serum amyloid P levels; Serum amyloid P component

Indexed keywords

AMYLOID P COMPONENT; SERUM AMYLOID P;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; REFERENCE VALUES; SERUM AMYLOID P-COMPONENT;

EID: 0031953594     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017035     Document Type: Article

References (27)

1. Coria F, Castano E, Prelli F, Larrondo-Lillo M, van Duinen S, Shelanski ML, Frangione B: Isolation and characterisation of amyloid P component from Alzheimer's disease and other types of cerebral amyloidosis. Lab Invest 1988; 58:454-458.
2. Zhan S, Veerhuis R, Kamphorst W, Eikelenboom P: Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Neurodegeneration 1995;4:291-297.
3. Duong T, Pommier EC, Scheibel AB: Immunodetection of the amyloid P component in Alzheimer's disease. Acta Neuropathol 1989; 78:429-437.
4. ab. Mol Immunol 1986;23:1045-1052.
5. Ying S-C, Gewurz AT, Jiang H, Gewurz H: Human serum amyloid P component oligomers bind and activate the classical complement pathway via the residues 14-26 and 76-92 of the A chain collagen-like stem region of C1q. J Immunol 1993;150:169-176.
6. Juul Sørensen I, Holm Nielsen E, Andersen O, Danielsen B, Svehag SE: Binding of complement proteins C1q and C4bp to serum amyloid P component (SAP) in solid contra liquid phase. Scand J Immunol 1996;44:401-407.
7. Schwalbe RA, Dahlbäck B, Nelsestuen GL: Heparin influence on the complex of serum amyloid P component and complement C4b-binding protein. J Biol Chem 1991;20:12896-12901.
8. de Frutos PG, Härdig Y, Dahlbäck B: Serum amyloid P component binding to C4b-binding protein. J Biol Chem 1995;270:26950-26955.
9. Juul Sørensen I, Andersen O, Holm Nielsen E, Svehag SE: Native human serum amyloid P component is a single pentamer. Scand J Immunol 1995;41:263-267.
10. Pepys MB, Butler PJG: Serum amyloid P component is the major calcium-dependent specific DNA-binding protein of the serum. Biochem Biophys Res Commun 1987;148:308-313.
11. Pepys MB, Dyck RF, de Beer FC, Skinner M, Cohen AS: Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979;38:284-293.
12. 2+-dependent binding of human serum amyloid P component to Alzheimer's β-amyloid peptide. J Biol Chem 1995; 270:10392-10394.
13. Danielsen B, Juul Sørensen I, Nybo M, Holm Nielsen E, Kaplan B, Svehag SE: Calcium-dependent and -independent binding of the pentraxin serum amyloid P component to glycosaminoglycans and amyloid proteins: Enhanced binding at slightly acid pH. Biochim Biophys Acta 1997;1339:73-78.
14. Skinner M, Vaitukaitis JL, Cohen AS, Benson MD: Serum amyloid P-component levels in amyloidosis, connective tissue diseases, infection and malignancy as compared to normal serum. J Lab Clin Med 1979;94:633-638.
15. Saïle R, Kandoussi A, Deveaux M, Descamps UJ, Hachulla E, Cachera C: Quantification of serum amyloid P by enzyme-linked immunosorbent assay. Clin Chem 1991;37:1742-1745.
16. Gertz MA, Skinner M, Cohen AS, Kyle RA: Nephelometric measurement of human serum amyloid P component (SAP). J Lab Clin Med 1979;94:633-638.
17. Nishiyama N, Iwamoto N, Kimura M, Arai H: Serum amyloid P component level in Alzheimer's disease. Dementia 1996;7:256-259.
18. Hawkins PN, Rossor MN, Gallimore JR, Miller B, Moore EG, Pepys MB: Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem Biophys Res Commun 1994;201:722-726.
19. Olsen H, Jeune B, Andersen-Ranberg K: Centenarians in a county of Denmark: Morbidity and functional capacity. Ugeskr Læger 1996; 158:7397-7401.
20. Folstein MF, Folstein SE, McHugh PR: 'Mini Mental State': A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
21. Tombaugh TN: The mini-mental stage examination: A comprehensive review. JAGS 1992; 40:922-935.
22. Iliffe S, Booroff A, Gallivan S, Goldenberg E, Morgan P, Haines A: Screening for cognitive impairment in the elderly using the mini-mental state examination. Br J Gen Pract 1990;40: 277-279.
23. O'Connor DW, Pollitt PA, Hyde JB, Fellows JL, Miller ND, Brook CPB, Reiss BB: The reliability and validity of the mini-mental state in the British community survey. J Psychiatr Res 1989;23:87-96.
24. Kalaria RN, Golde TE, Cohen ML, Younkin SG: Serum amyloid P in Alzheimer's disease: Implications for dysfunction of the blood-brain barrier. Ann N Y Acad Sci 1991;640:145-148.
25. Ohnishi S, Maeda S, Shimada K, Arao T: Isolation and characterization of the complete complementary and genomic DNA sequences of human serum amyloid P component. J Biochem 1986;100:849-858.
26. Garton MJ, Keir K, Vijaya Lakshmi M, Thompson EJ: Age-related changes in cerebrospinal fluid protein concentration. J Neurol Sci 1991;104:74-80.
27. Hutchinson WL, Noble GE, Hawkins PN, Pepys MB: The pentraxins, C-reactive protein and serum amyloid P component, are cleared and catabolized by the hepatocytes in vivo. J Clin Invest 1994;94:1390-1406.